These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 20470237)
1. Cellular and cytokine changes in the alveolar environment among immunocompromised patients during Pneumocystis jirovecii infection. Iriart X; Witkowski B; Courtais C; Abbes S; Tkaczuk J; Courtade M; Cassaing S; Fillaux J; Blancher A; Magnaval JF; Pipy B; Berry A Med Mycol; 2010 Dec; 48(8):1075-87. PubMed ID: 20470237 [TBL] [Abstract][Full Text] [Related]
2. Alveolar and blood T lymphocyte profiles in Pneumocystis jirovecii-positive patients: effects of HIV status. Iriart X; Witkowski B; Cassaing S; Abbes S; Menard S; Fillaux J; Valentin A; Linas MD; Tkaczuk J; Huget F; Huynh A; Hermant C; Escamilla R; Kamar N; Cointault O; Lavayssiere L; Alvarez M; Blancher A; Marchou B; Magnaval JF; Berry A J Infect Dis; 2011 Aug; 204(4):544-53. PubMed ID: 21791656 [TBL] [Abstract][Full Text] [Related]
3. The impact of concomitant pulmonary infection on immune dysregulation in Pneumocystis jirovecii pneumonia. Chou CW; Lin FC; Tsai HC; Chang SC BMC Pulm Med; 2014 Nov; 14():182. PubMed ID: 25409888 [TBL] [Abstract][Full Text] [Related]
4. Circulating and Pulmonary T-cell Populations Driving the Immune Response in Non-HIV Immunocompromised Patients with Zhang NN; Huang X; Feng HY; Huang LN; Xia JG; Wang Y; Zhang Y; Wu XJ; Li M; Cui W; Zhan QY Int J Med Sci; 2019; 16(9):1221-1230. PubMed ID: 31588187 [No Abstract] [Full Text] [Related]
5. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Alanio A; Desoubeaux G; Sarfati C; Hamane S; Bergeron A; Azoulay E; Molina JM; Derouin F; Menotti J Clin Microbiol Infect; 2011 Oct; 17(10):1531-7. PubMed ID: 20946413 [TBL] [Abstract][Full Text] [Related]
6. The importance of pro-inflammatory and anti-inflammatory cytokines in Pneumocystis jirovecii pneumonia. Chou CW; Lin FC; Tsai HC; Chang SC Med Mycol; 2013 Oct; 51(7):704-12. PubMed ID: 23488973 [TBL] [Abstract][Full Text] [Related]
7. Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients. Blount RJ; Daly KR; Fong S; Chang E; Grieco K; Greene M; Stone S; Balmes J; Miller RF; Walzer PD; Huang L PLoS One; 2017; 12(7):e0180212. PubMed ID: 28692651 [TBL] [Abstract][Full Text] [Related]
8. Scavenger receptor A dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii. Hollifield M; Bou Ghanem E; de Villiers WJ; Garvy BA Infect Immun; 2007 Aug; 75(8):3999-4005. PubMed ID: 17548480 [TBL] [Abstract][Full Text] [Related]
9. Alterations in T lymphocyte profiles of bronchoalveolar lavage fluid from SIV- and Pneumocystis carinii-coinfected rhesus macaques. Croix DA; Board K; Capuano S; Murphey-Corb M; Haidaris CG; Flynn JL; Reinhart T; Norris KA AIDS Res Hum Retroviruses; 2002 Mar; 18(5):391-401. PubMed ID: 11897041 [TBL] [Abstract][Full Text] [Related]
10. Cellular profiles of bronchoalveolar lavage fluid and their prognostic significance for non-HIV-infected patients with Pneumocystis jirovecii pneumonia. Lee JY; Park HJ; Kim YK; Yu S; Chong YP; Kim SH; Sung H; Lee SO; Kim MN; Lim CM; Kim YS; Koh Y; Woo JH; Choi SH J Clin Microbiol; 2015 Apr; 53(4):1310-6. PubMed ID: 25673796 [TBL] [Abstract][Full Text] [Related]
11. [Epidemiological characteristics of Long S; Mu XD; Zhang C; Su L; Jia P; Zhou PN; Wang GF Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2414-2417. PubMed ID: 30138986 [No Abstract] [Full Text] [Related]
12. Dectin-2 Is a C-Type Lectin Receptor that Recognizes Pneumocystis and Participates in Innate Immune Responses. Kottom TJ; Hebrink DM; Jenson PE; Marsolek PL; Wüthrich M; Wang H; Klein B; Yamasaki S; Limper AH Am J Respir Cell Mol Biol; 2018 Feb; 58(2):232-240. PubMed ID: 28886250 [TBL] [Abstract][Full Text] [Related]
13. [Positive Pneumocystis jirovecii PCR in immunocompromised patients with a systemic disease: infection or colonisation?]. Mekinian A; Queyrel V; Durand-Joly I; Moranne O; Denis G; Delhaes L; Morell-Dubois S; Lambert M; Launay D; Hachulla E; Hatron PY Rev Med Interne; 2010 Mar; 31(3):194-9. PubMed ID: 20045225 [TBL] [Abstract][Full Text] [Related]
16. Effect of bronchoalveolar lavage fluid from Pneumocystis carinii-infected hosts on phagocytic activity of alveolar macrophages. Lasbury ME; Lin P; Tschang D; Durant PJ; Lee CH Infect Immun; 2004 Apr; 72(4):2140-7. PubMed ID: 15039336 [TBL] [Abstract][Full Text] [Related]
17. Exogenous heat-killed Escherichia coli improves alveolar macrophage activity and reduces Pneumocystis carinii lung burden in infant mice. Empey KM; Hollifield M; Garvy BA Infect Immun; 2007 Jul; 75(7):3382-93. PubMed ID: 17485459 [TBL] [Abstract][Full Text] [Related]
18. Role of CD8 lymphocytes and neutrophilic alveolitis in Pneumocystis jiroveci pneumonia. Vahid B; Bibbo M; Marik PE Scand J Infect Dis; 2007; 39(6-7):612-4. PubMed ID: 17577827 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 and host defense against murine Pneumocystis pneumonia. Ruan S; McKinley L; Zheng M; Rudner X; D'Souza A; Kolls JK; Shellito JE Infect Immun; 2008 May; 76(5):2130-7. PubMed ID: 18332204 [TBL] [Abstract][Full Text] [Related]
20. Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation. Empey KM; Hollifield M; Schuer K; Gigliotti F; Garvy BA Infect Immun; 2004 Nov; 72(11):6211-20. PubMed ID: 15501746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]